KLRK1 and breast carcinoma: Besides recognition via the TCR and NKG2D, Vγ9/Vδ2 T cells have also been shown to target tumour cells including breast cancer cells upon engagement of CD16 (FcγRIII).24, 25, 26 In line with the expression of GD2 by CSC-like cells, we observed a relatively modest but detectable enhancement of Vγ9/Vδ2 T-cell responses toward CSC-like cells pretreated with the humanised anti-GD2 antibody hu14.18K322A (Figure 4d).